-
NU7441 (KU-57788) DNA-PK Inhibitor: Mechanism & Research Uti
2026-07-06
NU7441 (KU-57788) is a highly selective DNA-dependent protein kinase (DNA-PK) inhibitor with nanomolar potency. It is widely used in DNA repair research and oncology studies for its ability to sensitize cancer cells to DNA damaging agents and modulate cell cycle progression. APExBIO supplies NU7441 (A8315), supporting reproducible, high-fidelity DNA damage response experiments.
-
JSH-23: Targeted NF-κB Inhibitor for Advanced Inflammation R
2026-07-06
JSH-23 uniquely blocks NF-κB p65 nuclear translocation, enabling precise modulation of inflammatory signaling in both cellular and animal models. This article translates the latest evidence into actionable workflows and troubleshooting tactics, making it an indispensable tool for dissecting NF-κB–driven inflammation.
-
RESTRICT-seq Reveals New Epigenetic Drivers of SCC Resistanc
2026-07-05
The reference study introduces RESTRICT-seq, a time-gated CRISPR screening platform that uncovers novel epigenetic dependencies critical for squamous cell carcinoma (SCC) resistance. These findings advance the toolkit for dissecting chromatin regulators and highlight the translational potential of KAT6A inhibitors in cancer biology research.
-
Tyrothricin: Mechanistic Insights and Innovation in Antimicr
2026-07-04
Explore Tyrothricin as a peptide antibiotic mixture with broad-spectrum activity, focusing on advanced antimicrobial mechanisms and practical assay design. This article delivers unique scientific depth and fresh perspectives for infection research.
-
SB525334: Advanced TGF-beta1 Receptor Inhibitor Workflows in
2026-07-03
SB525334 empowers researchers to dissect TGF-beta1 signaling with precision, transforming experimental models in fibrosis, wound healing, and immune modulation. This guide delivers actionable protocols, comparative advantages, and troubleshooting strategies for deploying SB525334 in both in vitro and in vivo systems.
-
UTP Solution (100 mM): Enabling Epigenetic & RNA Innovation
2026-07-03
Explore the mechanistic role of UTP Solution (100 mM) in advanced RNA synthesis and epigenetic research, drawing strategic lessons from recent discoveries in olfactory receptor gene regulation. Gain actionable guidance on leveraging high-purity Uridine-5'-triphosphate trisodium salt for translational breakthroughs.
-
Hypoxia and Immunometabolism in Tumor Microenvironments
2026-07-02
This review dissects the complex interplay between hypoxia, metabolic reprogramming, and immune cell function within the tumor microenvironment. The paper provides mechanistic insights into how oxygen deprivation and altered glucose metabolism drive immune evasion, highlighting directions for metabolism-based therapeutic strategies in cancer.
-
Filipin III in Pulmonary Fibrosis: Cholesterol Probing in Di
2026-07-02
Explore how Filipin III, a polyene macrolide antibiotic, enables quantitative cholesterol detection in advanced pulmonary fibrosis models. This article uniquely connects membrane cholesterol visualization to translational lung research, offering new assay strategies and reference-driven insights.
-
Ferrostatins and the Inhibition of Oxidative Lipid Damage in
2026-07-01
This article reviews the pivotal study demonstrating that ferrostatin-1 and related arylalkylamines inhibit ferroptosis by blocking lipid peroxidation, thereby protecting cells across diverse disease models. The findings underscore the mechanistic centrality of lipid ROS in regulated cell death and highlight new avenues for antioxidant research.
-
Salmonella Haem Biosynthesis Suppresses Macrophage Phagocyto
2026-07-01
This study uncovers a methyltransferase-driven mechanism by which Salmonella Typhimurium upregulates haem biosynthesis, directly inhibiting macrophage phagocytosis and enhancing virulence. The findings redefine bacterial haem as a modulator of host-pathogen interactions, offering new perspectives for research into immune evasion and bacterial pathogenicity.
-
AMPK–SQSTM1 Feedback Loop Orchestrates Tumor Antioxidant Def
2026-06-30
This study reveals a double-positive feedback loop between AMPK and SQSTM1/p62 that enables dual activation of AMPK and NFE2L2/NRF2 pathways under metabolic stress. The findings provide mechanistic insight into tumor metabolic adaptation, especially in lung cancers with co-occurring STK11 and KEAP1 mutations, and suggest new avenues for targeted intervention.
-
α-Amanitin: Precision RNA Polymerase II Inhibition in Resear
2026-06-30
α-Amanitin is a highly specific inhibitor of RNA polymerase II, essential for dissecting transcriptional regulation and gene expression pathways. Its use enables reproducible, mechanistically validated workflows in developmental and cellular models. APExBIO's α-Amanitin (A4548) sets the benchmark for experimental integrity in molecular biology.
-
Filipin III: Precision Cholesterol Detection in Membranes
2026-06-29
Filipin III, a polyene macrolide antibiotic, transforms membrane cholesterol detection with its unparalleled specificity and fluorescence-based readout. This guide details optimized workflows, troubleshooting, and translational insights—empowering researchers to visualize cholesterol-rich microdomains and decode disease mechanisms with confidence.
-
Prochlorperazine: Dopamine D2 Antagonist in Melanoma Researc
2026-06-29
Prochlorperazine is a phenothiazine and potent dopamine D2 receptor antagonist with established antiemetic and emerging anticancer activities. It demonstrates inhibition of melanoma cell proliferation and migration at low micromolar concentrations and has documented risks, including rare neuroleptic malignant syndrome, at clinical doses. These characteristics make APExBIO’s Prochlorperazine a valuable, but carefully managed, tool in translational research.
-
Plerixafor (AMD3100): Translational Leverage in Cancer and S
2026-06-28
Explore the mechanistic and translational power of Plerixafor (AMD3100) as a gold-standard CXCR4 chemokine receptor antagonist for cancer metastasis inhibition, hematopoietic stem cell mobilization, and immune modulation. This article synthesizes recent head-to-head data, protocol guidance, and strategic outlooks, providing advanced insights for researchers moving from bench to bedside.